FluoGuide A/S (STO:FLUO)

Sweden flag Sweden · Delayed Price · Currency is SEK
43.30
+0.40 (0.93%)
Apr 28, 2026, 5:10 PM CET
9.34%
Market Cap 701.39M
Revenue (ttm) 318.79K
Net Income (ttm) -57.18M
Shares Out 16.35M
EPS (ttm) -4.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,983
Average Volume 8,776
Open 45.40
Previous Close 42.90
Day's Range 42.20 - 45.40
52-Week Range 28.00 - 47.60
Beta 0.36
RSI 61.73
Earnings Date May 27, 2026

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 7
Stock Exchange Nasdaq Stockholm
Ticker Symbol FLUO
Full Company Profile

Financial Performance

In 2025, FluoGuide's revenue was 220,000, a decrease of -42.86% compared to the previous year's 385,000. Losses were -39.46 million, 36.3% more than in 2024.

Financial numbers in DKK Financial Statements

News

FluoGuide Earnings Call Transcript: Q4 2025

Three positive Phase II trials, new partnerships, and a strengthened management team marked a pivotal year, with a net loss of DKK 39 million and a strong cash position. Regulatory progress with the FDA and upcoming clinical milestones set the stage for further growth.

2 months ago - Transcripts

FluoGuide Transcript: Investing in Life Science 2025

A novel imaging agent enables surgeons to better identify and remove cancer during surgery, with proven efficacy in multiple cancer types and strong FDA feedback. Market entry is prioritized in the U.S. with broad equipment compatibility and strategic partnerships.

7 months ago - Transcripts

FluoGuide Transcript: Investor Call

4 years ago - Transcripts